/BLTE

BLTE Stock - Belite Bio, Inc

Q: What is the analyst price target for BLTE?

Analyst price target information is not currently available for BLTE.

Q: What is BLTE's market cap?

Market capitalization information is not currently available for BLTE.

Healthcare|Biotechnology|NASDAQ

$156.95+1.40%

+$2.16 (+1.40%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

High Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+12.8%upside

Target: $177.04

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BLTE

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2020

FY2021

FY2022

FY2023

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-1.46

52W High$170.25

52W Low$49.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022	FY2021	FY2020
Revenue	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A	N/A	N/A
Operating Income	$-39,996,000	$-31,668,000	$-12,821,000	$-9,797,000	$-5,743,000
Net Income	$-36,144,000	$-31,632,000	$-12,648,000	$-9,666,000	$-5,753,000
Net Margin	N/A	N/A	N/A	N/A	N/A
EPS	$-1.18	$-1.19	$-0.63	$-0.40	$-0.62

Company Overview

Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.

Visit Website

Earnings History & Surprises

BLTE

Beat Rate

31%

Last 13 quarters

Avg Surprise

-33.9%

EPS vs Estimate

Beats / Misses

4/9

Last 12 quarters

Latest EPS

$-0.65

Q4 2025

EPS Surprise History

Q1 24

+30.6%

$-0.25vs$-0.36

Q2 24

+20.6%

$-0.27vs$-0.34

Q3 24

-10.7%

$-0.31vs$-0.28

Q4 24

+6.7%

$-0.28vs$-0.30

Q1 25

-6.7%

$-0.32vs$-0.30

Q2 25

-25.0%

$-0.45vs$-0.36

Q3 25

-6.4%

$-0.50vs$-0.47

Q4 25

-22.6%

$-0.65vs$-0.53

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 16, 2026	$-0.53	—	—	—
Q4 2025	Nov 10, 2025	$-0.53	$-0.65	-22.6%	✗ MISS
Q3 2025	Aug 11, 2025	$-0.47	$-0.50	-6.4%	✗ MISS
Q2 2025	May 13, 2025	$-0.36	$-0.45	-25.0%	✗ MISS
Q1 2025	Mar 17, 2025	$-0.30	$-0.32	-6.7%	✗ MISS
Q4 2024	Nov 12, 2024	$-0.30	$-0.28	+6.7%	✓ BEAT
Q3 2024	Aug 9, 2024	$-0.28	$-0.31	-10.7%	✗ MISS
Q2 2024	May 13, 2024	$-0.34	$-0.27	+20.6%	✓ BEAT
Q1 2024	Mar 11, 2024	$-0.36	$-0.25	+30.6%	✓ BEAT
Q4 2023	Nov 13, 2023	$-0.31	$-0.40	-29.0%	✗ MISS
Q3 2023	Aug 8, 2023	$-0.24	$-0.26	-8.3%	✗ MISS
Q2 2023	May 10, 2023	$-0.20	$-0.33	-65.0%	✗ MISS
Q1 2023	Mar 31, 2023	$-0.22	$-1.04	-374.4%	✗ MISS
Q3 2022	Sep 30, 2022	—	$-0.10	—	—
Q3 2022	Aug 10, 2022	$-0.23	$-0.12	+49.7%	✓ BEAT
Q2 2022	Apr 29, 2022	—	$-0.26	—	—
Q1 2022	Mar 31, 2022	—	$-0.05	—	—
Q3 2021	Sep 30, 2021	—	$-0.26	—	—
Q2 2021	Jun 30, 2021	—	$-0.25	—	—
Q1 2021	Mar 31, 2021	—	$-0.25	—	—